Navigation Links
Studies Presented at Neurology Conference Highlight Early Efficacy,,Long-Term Tolerability, and High Patient Satisfaction with,Betaseron

ly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT): Effects of Immediate vs. Early Onset of Interferon Beta-1b Treatment, American Academy of Neurology, 59th Annual Meeting

(2) By proportional hazards regression, adjusted for T2-lesion volume at screening.

(3) George Ebers et al: The Interferon Beta-1b 16-Year Long-term Follow-up Study: Predictive Clinical and MRI Markers

(4) Long-term treatment was defined as use of Betaseron for more than 80 percent of the time since the start of the pivotal trial (approx. 12 years or longer), while short-term treatment was defined as use for less than 10 percent of the time (approx. 1.6 years or less).

(5) Karl A Baum et al: Evaluation of Injection Site Pain and Reactions during Interferon Beta Treatment: Results from the BRIGHT (Betaseron(R) versus Rebif(R) InvestigatinG Higher Tolerability) Study.

* Trademarks are the property of their respective owners. Rebif(R) is a registered trademark of EMD Serono, Inc.

CONTACT: Marcy Funk, Bayer HealthCare, +1-973-305-5385

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
4. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
5. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
6. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
7. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
8. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
9. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
10. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
11. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
Post Your Comments:
(Date:5/13/2008)...XIENCE V in SPIRIT III Trial Experience Better, Lo...rombosis than Patients T...wswire-FirstCall/ -- Long-term data,presented for ...bott,s U.S.,pivotal trial studying the XIENCE(TM) ...trated that XIENCE V continues to deliver clinical...
(Date:5/13/2008)...ce, May 13 /- NicOx S.A.,(E...c. has initiated the,first in a series of planned ... patients, under the companies, collaborative agre...ertensive agents using NicOx,proprietary technolo...rom,the companies, joint research program, of whic...
(Date:5/12/2008)...ucts Expand Infection Prevention Business, DUBLIN...Health, a,global provider of products and services...h care, today announced it has completed the,acqui...the manufacturer of,infection prevention products ...rep(R) brand products are used widely in U.S. hosp...
(Date:5/12/2008)...wswire-USNewswire/ -- The Alliance for Lupus,Resea...resolution,supporting the goals and ideals of Nati...other,s Day. The resolution, introduced by Senator...lls on all Americans to take the,week of May 11th ... on,women,s health issues, and recognizes the impo...
Breaking Medicine Technology:XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 2XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 3XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 4XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 5NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc. 2NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc. 3Cardinal Health Completes Enturia Acquisition 2Lupus Under the Spotlight: U.S. Congress Shows Support for Women's Health Issues 2ETH Zurich researchers develop antibody test 2378 1ETH Zurich researchers develop antibody test 2378 2Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets 3660 1Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets 3660 2Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets 3660 3Covance to Present at Raymond James 29th Annual Institutional Investors Conference 13260 1AT4 wireless and Ekahau Partner to Deploy Combined Asset and Staff Tracking Solution for Hospitals 13258 1AT4 wireless and Ekahau Partner to Deploy Combined Asset and Staff Tracking Solution for Hospitals 13258 2
... HOUSTON, March 20, 2007 - An overexpressed prote...ng forced to devour,themselves, removing one of th...ell growth, researchers at The University of Texas...issue of Molecular,Cancer Research. , The protein ...,TG2, previously has been found by researchers at ...
...Phase 2 Clinical Trials Initiated, CRANBURY, N.J.,...s, a biopharmaceutical company developing small,mo...ones for the,treatment of a range of human genetic...sitive results from its recently completed,Phase 1...rate,AT2101) for Gaucher disease at the of Medica...
Other Medicine Technology:Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 2Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 3Amicus Therapeutics Presents Positive Results From Phase 1 Clinical,Studies of Plicera for Gaucher Disease 2Amicus Therapeutics Presents Positive Results From Phase 1 Clinical,Studies of Plicera for Gaucher Disease 3
(Date:5/13/2008)...to Serve as Senior Technology Advisor, SALT LAKE ...f Directors,of Sonic Innovations, Inc. (Nasdaq: S...ing aids, today announced that Andrew Raguskus has...us will continue as a member of the,Board of Direc...s a result,of Mr. Raguskus, announcement, the Boar...
(Date:5/13/2008)...NASDAQ: CRME TSX: COM, VANCOUVER, May 13 /PRNewsw...ME / TSX: COM) today reported financial results fo... unless specified otherwise, are,expressed in Cana...ally,Accepted Accounting Principles (Canadian GAAP...hange rate was CAD$1.00=US$0.9742., Results of Op...
(Date:5/13/2008)...itals that treat the poor from improving, study fi... -- The quality of care at hospitals that treat po...et hospitals, is lagging well behind hospitals tha..., These hospitals, which rely on state and fede...t have the money to improve the quality of care at...
(Date:5/13/2008)...y research could slow to a crawl unless regulators...researchers assert in an upcoming opinion piece. ,...fety research. It just isnt the right fit, says Na... at the Johns Hopkins Berman Institute of Bioethic...lished in the June issue of The Joint Commission J...
Breaking Medicine News(10 mins):Health News:Sam Westover to Serve as Chairman of the Board and Chief Executive Officer for Sonic Innovations 2Health News:Sam Westover to Serve as Chairman of the Board and Chief Executive Officer for Sonic Innovations 3Health News:Cardiome Reports First Quarter Results 2Health News:Cardiome Reports First Quarter Results 3Health News:Cardiome Reports First Quarter Results 4Health News:Cardiome Reports First Quarter Results 5Health News:Quality Lags at Safety-Net Hospitals 2Health News:Quality Lags at Safety-Net Hospitals 3Health News:Treating safety research like other clinical studies slows progress 2Health News:Treating safety research like other clinical studies slows progress 3
...MRI in surgical decision-making minimizes the pote...providing a new level of capability to predict sur...ngth. A 3-Tesla is one of the strongest commercial...hysicians describe a case study of five patients. ...
...was never known to be good. And the list of harmfu...ing. A school of thought, courtesy- research from ...o Clinic, has revealed the heightened risk of cart... pain in men who smoke, and suffer knee osteoarthr...
... A perceptive survey has established the prevaili...table on healthy diets, for quick fix snack option...ucted an elaborate nutrition survey which revealed...ong from a tender age. Parents and kids must know...
...easing number of tuberculosis cases detected annua...vernment, the Nation reports.// According to Somc...e Department of Disease Control, TB cases have inc...h officials' efforts. TB incidence in Thailand is ...
Other Medicine News:Health News:A New Technology for Safe Tumor Surgery 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine
For the qualitative detection of single and multiple drugs and drug metabolites in human urine
For the qualitative detection of single and multiple drugs and drug metabolites in human urine
For the qualitative differential detection of circulating Plasmodium falciparum (P.f) antigen and an antigen that is common to all four species of malaria:plasmodium falciparum (P.f), plasmodium viv
Medicine Products: